179 related articles for article (PubMed ID: 22213050)
1. PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.
Gawecka JE; Geerts D; Koster J; Caliva MJ; Sulzmaier FJ; Opoku-Ansah J; Wada RK; Bachmann AS; Ramos JW
Int J Cancer; 2012 Oct; 131(7):1556-68. PubMed ID: 22213050
[TBL] [Abstract][Full Text] [Related]
2. ERK MAP kinase is targeted to RSK2 by the phosphoprotein PEA-15.
Vaidyanathan H; Opoku-Ansah J; Pastorino S; Renganathan H; Matter ML; Ramos JW
Proc Natl Acad Sci U S A; 2007 Dec; 104(50):19837-42. PubMed ID: 18077417
[TBL] [Abstract][Full Text] [Related]
3. PEA15 promotes liver metastasis of colorectal cancer by upregulating the ERK/MAPK signaling pathway.
Tang B; Liang W; Liao Y; Li Z; Wang Y; Yan C
Oncol Rep; 2019 Jan; 41(1):43-56. PubMed ID: 30365128
[TBL] [Abstract][Full Text] [Related]
4. RSK2 activity is regulated by its interaction with PEA-15.
Vaidyanathan H; Ramos JW
J Biol Chem; 2003 Aug; 278(34):32367-72. PubMed ID: 12796492
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of phosphoprotein enriched in astrocytes 15 reverses the damage induced by propofol in hippocampal neurons.
Xian F; Li Q; Chen Z
Mol Med Rep; 2019 Aug; 20(2):1583-1592. PubMed ID: 31257496
[TBL] [Abstract][Full Text] [Related]
6. PEA‑15 contributes to the clinicopathology and AKT‑regulated cisplatin resistance in gastric cancer.
Jiang X; Zhang C; Li W; Jiang D; Wei Z; Lv M; Xie X; Sun X
Oncol Rep; 2019 Mar; 41(3):1949-1959. PubMed ID: 30569123
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
Alaminos M; Gerald WL; Cheung NK
Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15.
Bartholomeusz C; Itamochi H; Nitta M; Saya H; Ginsberg MH; Ueno NT
Oncogene; 2006 Jan; 25(1):79-90. PubMed ID: 16170361
[TBL] [Abstract][Full Text] [Related]
9. Integrin α4 Enhances Metastasis and May Be Associated with Poor Prognosis in MYCN-low Neuroblastoma.
Young SA; McCabe KE; Bartakova A; Delaney J; Pizzo DP; Newbury RO; Varner JA; Schlaepfer DD; Stupack DG
PLoS One; 2015; 10(5):e0120815. PubMed ID: 25973900
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529.
Kang S; Dong S; Guo A; Ruan H; Lonial S; Khoury HJ; Gu TL; Chen J
J Biol Chem; 2008 Feb; 283(8):4652-7. PubMed ID: 18156174
[TBL] [Abstract][Full Text] [Related]
11. MYCN gene amplification in patients with neuroblastic tumors.
Estiar MA; Fazilaty H; Aslanabadi S; Seifi M; Varghaei P; Rezamand A
Cell Mol Biol (Noisy-le-grand); 2014 Sep; 60(3):23-8. PubMed ID: 25231001
[TBL] [Abstract][Full Text] [Related]
12. RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics.
Sulzmaier FJ; Young-Robbins S; Jiang P; Geerts D; Prechtl AM; Matter ML; Kesari S; Ramos JW
Oncotarget; 2016 Nov; 7(48):79869-79884. PubMed ID: 27829215
[TBL] [Abstract][Full Text] [Related]
13. The protein phosphatase 4 - PEA15 axis regulates the survival of breast cancer cells.
Mohammed HN; Pickard MR; Mourtada-Maarabouni M
Cell Signal; 2016 Sep; 28(9):1389-1400. PubMed ID: 27317964
[TBL] [Abstract][Full Text] [Related]
14. MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.
Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ
Oncotarget; 2015 Jun; 6(17):15510-23. PubMed ID: 25860940
[TBL] [Abstract][Full Text] [Related]
15. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
[TBL] [Abstract][Full Text] [Related]
16. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG
Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890
[TBL] [Abstract][Full Text] [Related]
17. Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.
Knelson EH; Gaviglio AL; Tewari AK; Armstrong MB; Mythreye K; Blobe GC
J Clin Invest; 2013 Nov; 123(11):4786-98. PubMed ID: 24216509
[TBL] [Abstract][Full Text] [Related]
18. NLRR1 enhances EGF-mediated MYCN induction in neuroblastoma and accelerates tumor growth in vivo.
Hossain S; Takatori A; Nakamura Y; Suenaga Y; Kamijo T; Nakagawara A
Cancer Res; 2012 Sep; 72(17):4587-96. PubMed ID: 22815527
[TBL] [Abstract][Full Text] [Related]
19. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
[TBL] [Abstract][Full Text] [Related]
20. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma.
Gupta A; Williams BR; Hanash SM; Rawwas J
Cancer Res; 2006 Aug; 66(16):8100-8. PubMed ID: 16912187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
